Filing Flows › Tango Therapeutics (TNGX) › Q3 2025 › vs Q2 2025
Tango Therapeutics (TNGX) Q3 2025 vs Q2 2025 (quarter over quarter)
Tango Therapeutics's revenue rose $50.6M (17×) from $3.2M in Q2 2025 to $53.8M in Q3 2025.
Tango Therapeutics, Q3 2025: revenue $53.8M (+364% year over year), operating margin 26.2%, net earnings $15.9M, operating cash flow −$31.0M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q3 2025 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $53.8M | $3.2M | $50.6M | 17× |
| Other income, net | $1.8M | $2.1M | −$347K | -16% |
| Operating profit | $14.1M | −$41.0M | $55.0M | — |
| Costs & expenses | $39.7M | $44.1M | −$4.4M | -10% |
| Pre-tax earnings | $15.9M | −$38.8M | $54.7M | — |
| Research & development | $30.8M | $32.8M | −$2.0M | -6% |
| General & admin | $8.9M | $11.3M | −$2.4M | -21% |
| Income tax benefit | $10K | −$35K | $45K | — |
| Net earnings | $15.9M | −$38.9M | $54.7M | — |
| Operating cash sources | $54.0M | $4.9M | $49.2M | 11× |
| Depreciation | $555K | $625K | −$70K | -11% |
| Share-based compensation | $6.6M | $6.6M | $55K | +0.8% |
| Cash used in operations | $31.0M | $36.5M | −$5.6M | -15% |
| Working capital & other | $54.0M | $4.9M | $49.2M | 11× |
Questions
How much did Tango Therapeutics's revenue grow quarter over quarter in Q3 2025?
Tango Therapeutics's revenue rose $50.6M (17×) from $3.2M in Q2 2025 to $53.8M in Q3 2025.